Accreditation Council for Medical Affairs (ACMA)’s Post

Last day to register for our upcoming ACMA Online Webinar! Looking to break down silos and drive meaningful collaboration in your organization? Don’t miss Collaborate to Innovate: Effective Cross-Functional Strategies in Pharma, happening November 21, 2024, at 1 PM EST. Why Attend? Gain actionable insights from top industry leaders on how to align goals, overcome communication barriers, and create a collaborative culture in pharma. Meet Our Expert Speakers: - Luca Dezzani, MD – VP, US Oncology Medical Affairs, Johnson & Johnson: With extensive experience from Novartis, Eisai US, and AstraZeneca, Dr. Dezzani knows what it takes to lead impactful, cross-departmental initiatives. - Allen Lai, MD, PhD, BCMAS – Regional Specialty Medicine Medical Head, Ferring Pharmaceuticals: Bringing over 25 years of clinical and biopharma expertise, Dr. Lai has a proven track record in building collaborative teams that achieve results. What You’ll Learn: 🔹 Strategies for aligning team goals 🔹 Techniques to bridge communication gaps 🔹 Real-world case studies for practical application 📌 Secure your spot now and transform the way your team collaborates! 👉 https://lnkd.in/eSd_Spz8 Be part of this game-changing session and bring back new ideas to elevate your team’s performance. See you there! #Pharma #Webinar #Collaboration #PharmaceuticalIndustry #Leadership #ACMA #BCMAS #AI #Pharmaceutical #MedicalAffairs

The past few days were spent embedded in discussion regarding approaches to drug discovery and trial design that can tackle patient needs beyond “primary endpoints” and strictly clinical measures. It’s a fascinating—and frankly, enjoyable—topic, especially when listening to some of the world’s leading minds discuss and debate how we can be creative in future approaches. The FDA’s Peter Marks (🙌) gave the keynote and the audience hung on his every word. Communications around this topic are relevant across functions in the life sciences: grounded in clinical basis, leaders in corp comms, patient advocacy, access, IR and marketing all have an interest here. Wouldn’t it be progress to speak more directly of meaningful benefit(s)? Those who can communicate this clearly and directly will stand up and stand out, raising their value proposition and corporate/product brand reputation. I am proud to be associated with the National PKU Alliance, for their coordinating these few days and providing the intellectual space for such meaningful discussion – in this case, focused on #pku, but with much more broad application. And I am thankful for the sponsors who facilitated the conversation taking place: BioMarin Pharmaceutical Inc., Jnana Therapeutics, Moderna, PTC Therapeutics, Inc., Aptatek Biosciences, Sanofi, Tessera Therapeutics, ZOIA PHARMA LLC.

🎉 Exciting news - the 5th Optimizing Hybrid Clinical Trials Summit has launched!   Join over 80+ industry experts and world-class speakers from the likes of Pfizer, Eli Lilly and Company, Astellas Pharma, UCB, AbbVie, Jazz Pharmaceuticals and many more as we unite to explore practical case studies in building a budget and financial business case to run DCTs, securing end-to-end data flow, and managing data integrity and quality to operationalize hybrid trials.   Be one of the first to view the agenda here: https://ter.li/ruzr9m   Top highlights include: ✔ Valuable actionable insights from proven case studies ✔ 6 hours of networking with 80+ decision makers and facilitators planning clinical trials ✔Strategies to optimize hybrid clinical trials and enhance DE&I and patient access, improve operational efficiency and leverage remote data collection to demonstrate efficacy and safety in DCTs ✔15+ expert speakers including: Alanna Caffas, Craig Lipset, Dennis Salotti, Janet Moga, Len Rosenberg, Michael Podias and Xuemei Cai   Drug developers can secure their registrations free of charge❗   Find out more here - https://ter.li/ruzr9m

Explore insights from our latest blog, based on the 'What Companies Say' report, which delves into the evolving relationship between pharma companies and patient groups. Learn how leading pharma companies see this collaboration progressing and the impact on patient centricity. https://lnkd.in/evaHX4m8

In the recently published report by PatientView, BAYER's dedication to engaging with diverse patient voices is prominently featured. This report sheds light on our unwavering commitment to listen, learn from, and co-create with individuals who have lived experiences, advancing our mission towards #HealthForAll. But why does BAYER place such a high value on #partnering with #patient organizations? How do these collaborations influence our decision-making processes to address truly unmet needs? 🔍 Our partnership with patient groups is not just about consultation; it's about integration. By bringing these voices into the heart of our processes, we ensure that our efforts are not just innovative but also deeply empathetic and responsive to the needs of those we aim to serve. 🌱 From treating conditions once deemed untreatable to offering hope and working towards curing diseases, our collaboration with patient organizations is pivotal. It ensures that every step we take is a step closer to delivering greater impact and hope to the communities relying on us. We're motivated by the stories of hope and resilience we hear every day from patients around the world. Let's continue to work together, listen intently, and co-create solutions that bring us closer to a world where everyone has the opportunity to live a healthier life. #BAYER #PatientEngagement #Innovation #Healthcare #PatientVoice #CoCreation #Impact

Bridging MedTech and Pharma: A Conversation with Industry Leaders in Bad Homburg. Yesterday, our team from Arcondis joined industry leaders in Bad Homburg to greet and meet focusing on innovations, operations and security within Global Healthcare Companies. Key Insights from Our Discussion MedTech Innovations: The MedTech sector is advancing rapidly, particularly in digital healthcare solutions that enhance patient care and operational efficiency. Pharmaceutical Progress: The pharmaceutical industry remains essential, with continuous efforts in research and development to tackle chronic diseases and improve treatment options. Collaborative Potential: Our discussions emphasized the value of collaboration between MedTech and Pharmaceutical companies. By combining strengths, these industries can develop comprehensive solutions for complex healthcare challenges. Looking Ahead Our meeting in Bad Homburg highlighted the importance of ongoing collaboration and dialogue in driving healthcare innovation. At Arcondis, we are committed to fostering these connections to improve healthcare delivery and patient outcomes.

Pharma's R&D journey: Where science meets strategy, and innovation writes the script for tomorrow's healthcare saga. In the dynamic landscape of pharmaceuticals, innovation remains the cornerstone for driving breakthrough therapies and shaping the future of healthcare. Recent data highlights the substantial investment major pharmaceutical companies are making in research and development (R&D), underscoring their dedication to advancing medical science. A comparative analysis reveals the industry-wide commitment to scientific discovery and therapeutic advancement, with giants like Roche Pharmaceuticals, Novartis, and Lilly leading the charge. From strategic focus areas in oncology to neuroscience, companies like J&J and AbbVie are navigating market dynamics with precision, shaping the future of healthcare one breakthrough at a time. Yet, amidst this innovation frenzy, a groundbreaking study exposes a sobering truth: the high cost of innovation. With an average expenditure of $6.16 billion per new drug approval, the pharmaceutical landscape faces a critical need for greater efficiency in driving impactful medical breakthroughs. Let's delve into these intriguing insights together and explore the fascinating world of pharmaceutical innovation! 💊🔬 #PharmaInnovation #R&DInsights #InnovationUnleashed 💡🌍

Some insightful takeaways from Day Two at the marcus evans Group Evolution Summit, in the session on "Pioneering Transformation in Clinical Trial Operations": - "We need to make sure we’re not becoming more data centric and less patient centric in our approaches" - Darren Hart - Mirum Pharmaceuticals, Inc. - "Just because we’re using the ‘cool new thing’ doesn’t mean we’re advancing our operations" - Michael Rosenblatt, Roche - "Decision to use technology is often made by people who don’t actually have to use it" - Michael Rosenblatt, Roche Appreciating the honesty and open dialogue. These insights are valuable for both Sponsor and CRO teams and undoubtedly resonate with trial sites and patients. #clinicaltrials #innovation #sites #patients Natasha Hyatt-Khan Theron Burraway

Exciting Insights from an Advisory Board Meeting with a Pharmaceutical Company that I attended recently. I have always enjoyed being part of advisory board meetings as a Medical Writer because it allows me to interact with industry leaders and learn new things both from a business and healthcare perspective. I recently had this incredible opportunity to attend an advisory board meeting with a renowned Pharmaceutical Company (can't disclose name), and I couldn't be more thrilled to share some reflections on the experience! From the moment I walked into the room, I was surrounded by some of the brightest minds in the industry. The discussions were not only insightful but also inspiring, as we delved into the latest advancements in pharmaceuticals and the future of patient care in the oncology space. Key Takeaways: 1. Collaboration between industry leaders, healthcare professionals, and researchers is essential for driving innovation and improving patient outcomes. The synergy of diverse perspectives was truly powerful. 2. The emphasis on a patient-centric approach in drug development and delivery was a highlight. It’s reassuring to see how committed the Pharmaceutical Company was to prioritizing patient needs and experiences. 3. Engaging in discussions about emerging trends in oncology medicine and personalized medicine opened my eyes to the exciting possibilities ahead. The potential for transformative therapies is immense! 4. Connecting with fellow board members and industry experts was invaluable. Building these relationships is crucial for fostering future collaborations and sharing knowledge. I am grateful to the company for the invitation and for the opportunity to contribute to such meaningful conversations. It is experiences like these that reinforce my passion for the pharmaceutical industry and my commitment to making a positive impact. Looking forward to applying these insights in my work and continuing to engage with this vibrant community! #Pharmaceuticals #AdvisoryBoard #Innovation #PatientCare #Networking #medicalwriting #medcomms

The future of patient advocacy in the pharmaceutical industry hinges on continuous innovation, collaboration, and a steadfast commitment to placing patients at the forefront of all initiatives. Download Reuters brand new white paper to learn more: https://bit.ly/4fi2pRn Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!